secwatch.observer — SEC 8-K summary
======================================

Issuer:     DiaMedica Therapeutics Inc. (DMAC)
CIK:        0001401040
Form:       8-K
Filed at:   2023-08-14T23:59:59+00:00
Accession:  0001437749-23-023698
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

DiaMedica Therapeutics Q2 2023: clinical hold lifted, $37.5M private placement, cash $60.7M
--------------------------------------------------------------------------------

- FDA fully lifted clinical hold on ReMEDy2 Phase 2/3 trial of DM199 for acute ischemic stroke on June 21, 2023.
- Completed $37.5M private placement (~11M shares at $3.40; net proceeds ~$36.1M); cash runway into 2026.
- Cash, cash equivalents and investments of $60.7M as of June 30, 2023, up from $33.5M at Dec 31, 2022.
- R&D expenses increased to $6.2M for H1 2023 (up from $3.9M) due to clinical hold resolution and Phase 1C study.
- Phase 1C study in ACEi patients completed; all received full IV dose with no hypotension.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1401040/000143774923023698/0001437749-23-023698-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1401040/000143774923023698/dmtp20230814_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-023698

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer